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Patients with diabetes mellitus and symptomatic coronary artery disease are also likely to be hypertensive and, overall, are at very
high cardiovascular (CV) risk. This paper reports the findings of a posthoc analysis of the 1113 patients with diabetes mellitus in the
ACTION trial: ACTION itself showed that outcomes in patients with stable angina and hypertension were significantly improved
when a long-acting calcium channel blocking drug (nifedipine GITS) was added to their treatment regimens. This further analysis
of the ACTION database in those patients with diabetes has identified a number of practical therapeutic issues which are still
relevant because of potential outcome benefits, particularly in relation to BP control. For example, despite background CV
treatment and, specifically, despite the widespread use of ACE Inhibitor drugs, the addition of nifedipine GITS was associated
with significant benefits: improvement in BP control by an average of 6/3mmHg and significant improvements in outcome. In
summary, this retrospective analysis has identified that the addition of nifedipine GITS resulted in improved BP control and
significant outcome benefits in patients with diabetes who were at high CV risk. There is evidence to suggest that these findings
are of direct relevance to current therapeutic practice.
1. Introduction
The optimal management of patients with type 2 diabetes
mellitus requires a multiplicity of drug treatments: not only
for glycaemic control but also for nephroprotection and
for reducing cardiovascular (CV) risk. Since CV disease,
particularly coronary artery disease (CAD), accounts for
around 60% of deaths in people with type 2 diabetes mel-
litus, “cardioprotective” drugs are obviously of fundamental
importance [1, 2]. Furthermore, since many of these patients
with diabetes also have hypertension and since there is
good evidence that “tight” blood pressure (BP) control
significantly reduces CVmorbidity and mortality in diabetic,
hypertensive patients (usually by means of combination drug
treatment), optimal antihypertensive treatment is central
to the overall therapeutic strategy [3, 4]. Although it is
recommended that the antihypertensive treatment regimen
includes drugs which block the renin-angiotensin system
(RAS blockade) (mainly because of the evidence suggestive
of nephroprotection) [5–7], it is important to remember
that RAS blockade has no direct antianginal activity. Thus,
there is not yet agreement on the “best practice” antihyper-
tensive/antianginal treatment combination for patients with
diabetes, hypertension, and symptomatic CAD [8–12].
The ACTION trial (published in 2004) established that
the addition of nifedipine (in its long-acting GITS formula-
tion) improved the prognosis of patients with chronic stable
angina, particularly in those with concomitant hypertension
[13, 14]. This further analysis specifically addresses practical
treatment issues in more than 1000 patients with high CV
risk which was attributable to the combination of established
CAD, diabetes, and hypertension. Attention is directly
focused on the role of improved BP control by means of the
calcium channel blocking drug (CCB), nifedipine, which has
well-recognised pharmacological properties known to lead
to BP reduction, symptomatic improvement in angina, and
amelioration of underlying myocardial ischaemia [15, 16].
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2. Patients and Methods
The design, selection criteria, methods, and main results of
the ACTION trial have been published in detail previously
[13, 14, 17]. In brief, 7655 patients with symptomatic, stable
angina pectoris were randomized to receive either nifedipine
GITS (n = 3825) or matching placebo (n = 3840). In
addition to angina, patients had to have either a history of
myocardial infarction (MI), or proven angiographic coro-
nary artery disease, or a positive exercise test or perfusion
defect. The left ventricular ejection fraction had to be at
least 40%. The definition of diabetes mellitus (DM) was
simplistically based upon the “clinical history” according to
the ACTION study investigators with the caveat that patients
with unstable type 1DM were ineligible [17]. The starting
dose of nifedipine GITS or placebo was 30mg once daily,
increasing to 60mg once daily within 6 weeks. It is important
to note that these treatments were in addition to “best
practice” CV drug therapy (at the time), with a follow-up
period of 4 to 5 years.
This further analysis has explored a number of aspects
of the eﬀectiveness of treatment with nifedipine GITS in
patients with the combination of chronic stable angina and
diabetes mellitus.
3. StatisticalMethods
Five composite endpoints were investigated: these were all
prespecified in the ACTION protocol and investigated as
part of the main study analysis. These endpoints were
defined as: the primary eﬃcacy endpoint (all-cause mortality,
MI, refractory angina requiring coronary angiography, new
overt heart failure requiring hospitalization, and peripheral
revascularisation); the primary safety endpoint (all-cause
mortality, MI, and debilitating stroke); any cardiovascular
event (primary endpoint for eﬃcacy minus noncardiovascu-
lar death); any death, cardiovascular event, or procedure (i.e.,
the primary endpoint for eﬃcacy plus coronary angiography,
percutaneous coronary intervention (PCI), and coronary
bypass surgery (CABG)); and any vascular event or procedure
(i.e., the primary endpoint for eﬃcacy minus noncardiovas-
cular death and new overt heart failure plus PCI and CABG.
Patients diagnosed with diabetes mellitus at baseline
were compared to the nondiabetic patients in terms of
a number of baseline characteristics using two-sample t-
tests and Fisher’s exact test for continuous and categorical
variables, respectively. Using Fisher’s exact test, concomitant
medications were compared for the two patient groups;
diabetics and nondiabetics on the same treatment were
also compared. To illustrate the antihypertensive eﬀect of
nifedipine GITS, the numbers of patients (%) achieving the
arbitrary target levels of either 140/90 or 130/80mmHg were
summarised by year, diabetic status, and treatment group
and are presented in the form of bar charts. The safety of
nifedipine was further explored by plotting themean changes
in glucose and creatinine over time by diabetic status and
treatment group.
Hazard ratios and 95% confidence intervals were
obtained in the analyses of the five composite endpoints
from Cox proportional hazards models for the treatment
eﬀect within each of the diabetic subgroups; interactions
between diabetes and treatment were also investigated.
Subgroup analyses of patients receiving RAS blockade are
also presented. All analyses were carried out on the intention-
to-treat principle using SAS v 9.1.
4. Results
Of 7665 patients started on study medication, 1113 (14.5%)
were categorised with diabetes mellitus at baseline: the great
majority, approximately 85%, were classified as patients
with type 2 diabetes. The baseline clinical characteristics
are summarized by diabetic status in Table 1. The patient
cohorts—those with diabetes and those without diabetes—
were similar in terms of age, gender, and a number of clinical
features. However, there were some diﬀerences, for example,
in the patients without diabetes there were more current
cigarette smokers and more patients with total cholesterol
above 5mmol/l. These diﬀerences obviously would aﬀect
CV risk in the group without diabetes but the adverse
impact of diabetes itself outweighs these small percentage
diﬀerences and this is reflected in the rates for events and
procedures shown in Table 2, whereby the patients with dia-
betes invariably have higher rates for all-cause death, major
events, vascular procedures, and so forth. With particular
respect to hypertension there were obvious, statistically
significant and clinically relevant diﬀerences: for example,
56% of the patients with diabetes were already receiving drug
treatment for hypertension but 60% remained uncontrolled
with BP above the conventional target of 140/90mmHg
(the mean BP was 141/80mmHg). The corresponding values
in the patients without diabetes were significantly diﬀerent
with 39% receiving antihypertensive drug treatment, with
51% remaining uncontrolled (>140/90) and a mean BP
of 137/80mmHg. The attainment of diﬀerent levels of BP
control is illustrated in Figure 1. After 4-year of nifedipine
treatment, 58% of the patients with diabetes had achieved
BP <140/90 compared to 45% in those treated with placebo:
similar diﬀerences were apparent for the patients without
diabetes at, respectively, 66 and 52% Figure 1(a). Tighter
BP control to <130/80mmHg was achieved in 27% of the
patients with diabetes treated with nifedipine compared to
17% of patients on placebo; again, similar proportions at,
respectively, 32 and 23% were found in the nondiabetic
patients Figure 1(b).
Concomitant medications are summarised in Table 3.
Throughout the study there were small but significant
diﬀerences between the treatment groups. Patients with
diabetes were more likely to receive drugs acting on the
renin-angiotensin system (RAS blockade), either an ACE-
inhibitor or an angiotensin receptor blocker, either at
baseline or at some time during the study. For example,
34% of the patients with diabetes randomised to nifedipine
were receiving RAS blockade at baseline compared to 20%
of the nondiabetic patients (P < .0001) and correspondingly
65% compared to 40% at any time during the study (P <
.0001). Additionally, both patients with and without diabetes
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Table 1: Summary of patient characteristics (at baseline).
Without-diabetes
(n = 6552)
With-diabetes
(n = 1113) P-value
Basic
Demography
Age (years) 63.4 (9.4) 63.9 (8.9) .082
Males 5224 (80%) 860 (77%) .065
Body Mass
Index (kg/m2)
27.3 (3.7) 28.7 (4.2) <.0001
Clinical Features
History of MI 3326 (51%) 572 (51%) .721
History of
PTCA
1720 (26%) 296 (27%) .825
History of
CABG
1486 (23%) 303 (27%) .001
Claudication 451 (7%) 174 (16%) <.0001
Transient
ischaemic attack
247 (4%) 55 (5%) .067
Stroke 139 (2%) 31 (3%) .185
Drug Treatment
(i) for
hypertension
2577 (39%) 621 (56%) <.0001
(ii) for
hyperlipidaemia
4446 (68%) 754 (68%) .945
Laboratory
Variables
Glucose
(mmol/l)
4.46 (1.17) 9.71 (3.89) <.0001
Creatinine
(umol/l)
97.2 (17.7) 97.2 (17.7) .890
Cardiovascular
Variables
Pulse Rate
(beats/min)
63.8 (10.1) 67.1 (10.7) <.0001
Systolic BP
(mmHg)
136.9 (18.8) 140.7 (18.0) <.0001
Diastolic BP
(mmHg)
79.9 (9.5) 79.8 (9.4) .719
Risk Factors
Current Smoker 1204 (18%) 152 (14%) .0001
Total cholesterol
≥5.0mmol/L 4167 (65%) 648 (60%) .002
Body Mass
Index
≥30.0 kg/m2
1368 (21%) 376 (34%) <.0001
Blood pressure
≥140/90mmHg 3309 (51%) 668 (60%) <.0001
Any of the above 5669 (87%) 984 (88%) .094
Data are presented as number of patients (%) or mean (SD).
receiving nifedipine were significantly less likely to receive
additional antihypertensive treatment during the study. For
example, in the cohort of patients with diabetes, RAS
blockade was incorporated at some time during the study
in 72% of patients randomized to placebo (65% in the
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Figure 1: Patients (%) in diﬀerent subgroups achieving BP Control
at <140/90 (a) and <130/80mmHg (b).
nifedipine group; P < .02) and diuretic was added in 53%
of patients (46% in the nifedipine group; P < .05).
The incidental eﬀects of 4 years treatment with nifedipine
on glucose control and on renal function (serum creatinine)
are illustrated in Figure 2. There were slight increases over
time in serum creatinine: these increases were seen in both
treatment groups and for both diabetic and nondiabetic
patients. Similar findings were seen for plasma glucose with a
trend for smaller increases in the nifedipine treatment group
after 6 months. None of the diﬀerences, for either creatinine
or glucose, attained statistical significance.
The treatment eﬀects are summarised by diabetic status
for each of the major endpoints in Figure 3. Although
there were no statistically significant diﬀerences, there was
an overall pattern whereby the magnitude of the benefits
associated with nifedipine treatment was at least as great in
the diabetic cohort. For example, the composite endpoint
of CV events, death and procedures showed a significant
reduction by 10% in the nondiabetic population and a
significant reduction of 19% in the diabetic population.
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Table 2: Rates (per 100 patient years) for individual end-points.
End-point
Without diabetes With diabetes ∗P-value
Nifedipine Placebo
Hazard ratio
(95% C. I.)
Nifedipine Placebo
Hazard ratio
(95% C. I.)
All-cause death 1.53 1.43 1.07 (0.89, 1.28) 2.27 2.15 1.05 (0.74, 1.51) .942
Myocardial
Infarction
1.36 1.25 1.09 (0.9, 1.32) 2.02 2.28 0.89 (0.61, 1.29) .326
Heart Failure 0.37 0.51 0.72 (0.52, 1.01) 1.01 1.52 0.67 (0.41, 1.49) .771
Stroke 0.33 0.49 0.67 (0.47, 0.94) 0.9 0.73 1.22 (0.67, 2.23) .086
Coronary Artery
Bypass Grafting
1.46 1.92 0.76 (0.64, 0.9) 2.61 2.92 0.9 (0.64, 1.25) .395
Percutaneous
Coronary
Intervention
2.08 2.21 0.94 (0.81, 1.1) 2.57 3.11 0.83 (0.59, 1.15) .482
Peripheral
Revascularisation
0.72 0.56 1.27 (0.96, 1.67) 1.21 1.05 1.16 (0.7, 1.94) .749
Refractory Angina 0.76 0.86 0.89 (0.7, 1.14) 1.09 1.50 0.73 (0.45, 1.18) .47
Coronary
Angiography
5.22 6.29 0.83 (0.75, 0.92) 6.93 9.28 0.75 (0.61, 0.93) .384
∗P-value for diabetes status/treatment interaction term.
Table 3: Further details of cardiovascular drugs and diabetes treatments.
Without diabetes With diabetes P-value for
Nifedipine
P-value for
Placebo
comparisonNifedipine Placebo P-value Nifedipine Placebo P-value comparison
Baseline
Cardiovascular
Drugs
Beta-Blocker 2583 (79%) 2632 (80%) — 450 (79%) 434 (80%) — 1.000 .818
ACE-I or ARB 664 (20%) 678 (21%) — 195 (34%) 202 (37%) — <.0001 <.0001
Diuretic 350 (11%) 359 (11%) — 82 (15%) 88 (16%) — .012 <.0001
Any Blood
Glucose — — — 434 (77%) 419 (77%) — — —
Lowering Rx
Insulin — — — 88 (16%) 96 (18%) — — —
Metformin — — — 177 (31%) 159 (29%) — — —
Sulfonylureas — — — 302 (53%) 282 (52%) — — —
At any time
Cardiovascular
Drugs
Beta-Blocker 2868 (88%) 2943 (89%) .094 506 (89%) 495 (91%) .486 .438 .406
ACE-I or ARB 1298 (40%) 1583 (48%) <.001 371 (65%) 393 (72%) .020 <.0001 <.0001
Diuretic 1130 (35%) 1256 (38%) .004 261 (46%) 287 (53%) .031 <.0001 <.0001
The rates of major individual end-points and procedures
are shown in Table 2: there were no statistically significant
diﬀerences. The all-cause death rate was nonsignificantly
higher but the benefits attributable to nifedipine GITS
reflected fewer major clinical events, fewer interventions,
fewer investigations, and fewer hospitalizations for refractory
angina.
The subgroup analysis of those patients with diabetes
receiving RAS blockade showed a similar pattern of benefit
for those patients receiving nifedipine GITS in addition to
RAS blockade (Figure 4).
5. Discussion
The combination of hypertension and coronary artery
disease occurs more often in patients with type 2 diabetes
than in matched controls [2]. This analysis of the subgroup
of patients with diabetes mellitus within the ACTION
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Figure 2: Laboratory values: creatinine (b,d) and glucose (a,c) in patients with diabetes (c,d) and without diabetes (a,b).
study population focuses attention on practical therapeutic
issues in such high-risk patients. The weaknesses of such
retrospective, subgroup analyses (with relatively modest
statistical power) are readily acknowledged but the findings
and resultant conclusions remain directly relevant to current
clinical practice.
The ACTION study involved adding either nifedipine
GITS or placebo to “best practice” CV treatment and it was
disappointing to find that, at baseline, 88% of the patients
with diabetes mellitus (and 87% of the patients without
diabetes) had treatable CV risk factors over and above
their underlying CAD. It is particularly disappointing that
“best practice treatment” in patients with CAD and diabetes
“tolerated” BP levels above 140/90mmHg in 60% and total
cholesterol above 5mmol/l also in 60% of patients. Whilst
awareness of the importance of risk factor management and
the relevance of “aggressive” treatment targets has consid-
erably increased in recent years, these percentages are not
markedly diﬀerent from those reported from USA in 2009
[18]. In this American survey, 54.5% of the patients with
diabetes had inadequate BP control (>130/80mmHg), and
53.5% had suboptimal cholesterol levels (total cholesterol
>5mmol/l). This survey additionally noted that the triple
combination of glycaemic control, BP control and lipid
control was achieved in only 12.2% of patients: therefore,
87.8% had at least one uncontrolled CV risk factor [18].
Thus, although risk factor management has progressively
and significantly improved in recent years, there remain
shortcomings in the management of patients with diabetes
and high CV risk: these are precisely the shortcomings
identified in this posthoc ACTION analysis.
Focusing on antihypertensive drug treatment, the addi-
tion of nifedipine GITS in ACTION resulted in a significant
improvement in BP control through a mean BP reduction
of 6/3mmHg. This is both a statistically significant improve-
ment and a clinically relevant improvement. There is clear
evidence that an improvement of this magnitude in BP
control will significantly improve prognosis in patients with
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Figure 4: Major outcomes in patients receiving combination treatment with RAS blockade and Nifedipine GITS.
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diabetes [3, 4]. However, closer scrutiny of the BP data in the
cohort of patients with diabetes reveals that BP control at a
target level of less than 140/90 was attained in less than 50%
of patients (and a target of less than 130/80mmHg in only
27%, albeit compared to 16% at baseline). Some possible
practical explanations for these disappointing results are
obviously that diabetic hypertension is particularly diﬃcult
to control and/or that the importance of BP control was
undervalued (and the CV risk underestimated) by the
participating physicians at that time. Irrespective of the
quality and nature of the background treatment, the addition
of nifedipine GITS in ACTION was associated not only
with improved BP control but also with significant outcome
benefits in the cohort of patients with diabetes. Clearly, it is
possible that the outcome benefits were simply attributable
to the improvement in BP control and that the addition of a
diﬀerent long-acting CCB, such as amlodipine or felodipine,
might have achieved similar success. However, although
amlodipine has similar pharmacological activity and a simi-
lar therapeutic profile [19], there are no corresponding data
in patients with the clinical profile of diabetes, hypertension
and symptomatic, stable CAD. Similarly, there is no directly
comparable evidence with felodipine, but the results of the
HOT study provide supportive evidence of the benefits of
modest improvements in BP control in high-risk patients
with diabetes [3].
Another consideration relates to the use of RAS blockade.
The recently revised European Hypertension guidelines con-
tinue to recommend RAS blockade as a first-line treatment
for hypertension in patients with diabetes, but this reflects
the evidence relating to proteinuria and nephroprotection
and not directly to “cardioprotection” [20]. Thus, in the
patients with diabetes in ACTION, “reliance” may have been
placed on the putative cardioprotective properties of drugs
blocking the renin-angiotensin system (RASblockade) rather
than the attainment of improved BP control [21]. In this
regard, between 65 and 72% of the patient population with
diabetes in ACTION received these drugs at some time
during the study. However, RAS blocking drugs have no
direct antianginal/antiischaemic properties (in contrast to
nifedipine [22]). It is interesting to note that favourable
results (i.e., benefits of greater magnitude) were obtained in
the whole ACTION population in those patients receiving
nifedipine GITS in addition to RAS blockade [23].
In conclusion, although this posthoc analysis reflects
clinical practice from almost a decade ago, the most recent
survey from the USA identifies that there remain problems
with optimal CV risk factor management in patients with
diabetes and high CV risk. Firstly, in such high-risk patients
with diabetes and increased levels of BP (and cholesterol),
targets are diﬃcult to achieve. However, significant improve-
ments are possible: for example, improved BP control by
the simple means of additional drug treatment (in this
case, a long-acting CCB). Secondly, in treatment specific
terms, the evidence suggests that RAS blockade alone (with
either an ACE inhibitor or an angiotensin receptor blocker)
may not provide suﬃcient BP control or “cardioprotection”.
In such patients, with high CV risk because of diabetes,
hypertension and symptomatic, chronic stable angina, there
were statistically significant benefits via increased rates of
BP control and improved outcomes (and fewer vascular
procedures) when a diﬀerent type of drug (nifedipine GITS )
with proven antihypertensive, antianginal and antiischaemic
properties was added to the multi-drug treatment regimen.
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